RPS Company News

RPS Expands Executive Team with Senior Industry Experience

Plymouth Meeting, Pa USA – July 1 2006

Daniel M. Perlman, CEO / CHB announced today the appointments of Harris Koffer, PharmD as President and COO of Research Pharmaceutical Services, Inc. (RPS) and Janet L. Brennan as Chief Clinical Officer and Executive Vice President, Global Operations of Research Pharmaceutical Services. Research Pharmaceutical Services is the first Pharmaceutical Resource Organization (PRO) providing services to the Pharmaceutical and Biotechnology industries for clinical drug development.

Prior to joining RPS, Dr. Koffer served as Corporate Executive Vice President and President, Cardiac Safety Services, for Medifacts International; Vice President, Clinical Trials and Pharmaceutical Business Development, for Quest Diagnostics; Vice President and General Manager of Covance Clinical Services and President of Covance Periapproval Services. In these roles, he was responsible for global central laboratory services as well as full service clinical research and development capabilities for Phases 1 through 4 of drug development.

In addition to over 25 years of experience in clinical drug development, he has served as Adjunct Assistant Professor of Pharmacy in Medicine at the University of Pennsylvania School of Medicine and Clinical Associate Professor of Pharmacy at the Philadelphia College of Pharmacy and Science.

Dr. Koffer has published and presented numerous papers in the fields of Cardiovascular Clinical Pharmacology and Pharmacoeconomics. He earned both a BS in Pharmacy and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science and completed a Fellowship in Clinical Pharmacology at Thomas Jefferson University Hospital in Philadelphia.

“We are both privileged and excited to have Dr. Koffer join RPS. In the last six years RPS has grown from a small player in clinical research to a leader in unique solutions to the industry, as well as a large player in the outsourcing and integration of clinical trials,” said Dan Perlman. “Combining our PRO / BPO models with our CRO capabilities has led to this explosive growth. As RPS expands both globally and in the different Phases of clinical research, RPS will continue to add expertise and leadership in developing our world class organization; and continue our goal of combining quality, speed and structure to offer solutions to the R&D Pharma/Bio sector that bring total cost reductions to clinical development.”